57 results about "Healthy donor" patented technology

A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.

The invention discloses a method for jointly preparing CAR-VGamma9VDelta2T cells and CAR-NKT cells, comprising the steps of 1) adding peripheral blood mononuclear cells to a cell medium, pre-activating VGamma9VDelta2T cells and NKT cells therein, and amplifying the VGamma9VDelta2T cells and NKT cells by selective in-vitro activation; 2) transducing the mixed cells of step 1) by using a lentiviral vector carrying chimeric antigen receptor's gene sequence. It is possible to carry out standard and batch preparation herein by using GammaDeltaT of a healthy donor; the purities of the VGamma9VDelta2T cells and NKT cells in the application can reach 60% and 30% and above respectively without purification, and therefore pre-purification can be omitted; in-vivo activation proliferation level and existence time of CAR-VGamma9VDelta2T cells and CAR-NKT cells jointly prepared by using the method can be controlled through clinical medication.

The invention discloses a screening method of an intestinal flora transplantation donor. The method comprises the steps of firstly communicating with a donor, informing the donor of a flora transplantation concept and filling out notes of a questionnaire, and screening out qualified healthy donors through the processes of donor basic information registration, clinical evaluation, gastrointestinaltract pathogen detection and blood detection, wherein the expiration date of the donors is three months. And the healthy donor needs to be screened again in the gastrointestinal tract pathogenic bacteria detection and blood detection processes after three months, and only the donor meeting the requirements needs to be screened again and is the qualified donor. The invention aims to establish a scientific and reasonable screening method for the flora transplantation donors, which can improve the quality of healthy donors to ensure the safety and the effectiveness of transplantation to the maximum extent and provide basis and reference for the national establishment of relevant standards.

The invention provides a CAR-NK cell culture method. The culture method comprises the following steps of S1, collecting peripheral blood of a healthy donor, and separating to obtain peripheral blood mononuclear cells; S2, sorting out NK cells from peripheral blood mononuclear cells; S3, infecting the NK cells in the step S2 with a lentiviral vector with a chimeric antigen receptor gene; and S4, carrying out multiplication culture on the CAR-NK cells by using a culture medium containing interleukin-2, inositol, quercetin glucoside, formononetin, sheep placenta and galactose to obtain a large number of CAR-NK cells. The CAR-NK cell culture method disclosed by the invention is simple to operate, and the cultured NK cells are high in purity, large in quantity, large in quantity of CAR-NK cellsand high in killing activity.

The invention discloses application of a fecal flora in preparing a micro-ecological preparation for treating chronic hepatitis B and relates to the technical field of intestinal micro-ecology. A transplanting method of the fecal flora comprises the following steps of 1) separating and purifying the fecal flora in healthy donor feces; and 2) transplanting the fecal flora into an intestinal tract of a patient, and remodeling the unbalanced intestinal flora of the patient to a balanced state. The fecal flora can be applied to preparing a drug for treating HBeAg negative chronic hepatitis B, canbe used by combining with other antiviral drugs, such as entecavir, as long as no other adverse effect, such as anaphylaxis, is generated and can be applied to preparing a drug for relieving disease response of a patient with the chronic hepatitis B, a drug for lowering the HBsAg content of the patient with the chronic hepatitis B, a drug for regulating the immune function of the patient with thechronic hepatitis B and a health care product, a beverage, a enteral nutrition preparation or a dietary supplement for relieving or adjunctively treating the chronic hepatitis B.

The invention relates to a blood metabolite marker for diagnosing multiple myeloma, and application. Untargeted metabolomics detection are firstly performed on a healthy donor (HD), and the marrow andperipheral blood sample of a primary-care patient of multiple myeloma (mm) to screen out 5 metabolites that have significant differences in marrows and peripheral blood samples, wherein the 5 metabolites are respectively L_Proline, L_Aspartic acid, L_Cystine, Stearic acid, and Palmitic acid. The analysis result of the ROC curve shows that the 5 different metabolites as a whole can more accuratelydiagnose MM. Targeted metabolomics detection further confirmed that the metabolome composed of these 5 metabolites is an ideal MM diagnostic method. The invention can accurately diagnose MM and is ofgreat significance for promoting the diagnosis of MM in basic research and clinical treatment.

Described herein are methods and compositions for the treatment of skin conditions associated with dysbiosis. Skin conditions associated with dysbiosis for treatment using compositions and methods described herein include atopic dermatitis, eczema, dermatitis, psoriasis, rosacea, and acne. Compositions include single or more than one strain of healthy donor derived bacteria for administration to provide therapy for skin conditions associated with dysregulated microbiota. Such compositions include gram negative and/or gram positive bacteria.

A therapeutic method for preventing, suppressing, or treating an autoimmune disease is described. This method involves administering to a patient suffering from an autoimmune disease an effective amount of a composition containing an allogeneic or autologous leucocyte cell population derived from a healthy donor. The composition is administered by subcutaneous injection and induces an immunological response in recipient patients sufficient to reduce incidence, prevalence, frequency, or severity of the autoimmune disease.

The invention provides a method for assessing or determining activity of a test Compound on modulation of gene product levels comprising culturing cells, contacting at least one of the cultured cells with a lipid-rich fraction, contacting at least one of the cultured cells with the test Compound, determining the presence of a gene product of at least one cell of the cultured cells and, optionally, determining the presence of the gene product of at least one cultured cell not contacted with the test Compound. To assess human conditions most fully, it is preferred that the cell is of human origin, for example, a peripheral blood monocyte taken from a healthy donor.

HER2+ invasive breast cancer (IBC) patients with residual disease following neoadjuvant chemotherapy have an anti-HER2 Type 1 T helper (Th1) cell immune deficit and a significant risk of recurrent disease. It has been shown that anti-HER2 CD4+ T-cell responses incrementally decrease along the breast cancer continuum - a robust response in healthy donors and patients with benign disease, a depressed response in patients with HER2+ ductal carcinoma in situ, and a nearly absent response in patients with HER2+ IBC. This invention relates to a method of creating a microenvironment for culture expansion of T cells. The expanded T cells can be used for a variety of therapeutic and research purposes.

The invention discloses application of a reagent for detecting CKAP4 in a sample and a bladder cancer detection kit. The CKAP4 is not only highly expressed in bladder cancer cell lines and exosomes secreted by the bladder cancer cell lines, but more importantly, the CKAP4 is remarkably and highly expressed in urine exosomes of bladder cancer patients clinically, but the expression quantity in urinary system cancers such as prostatic cancer and renal cell carcinoma, urinary system inflammation and urine exosomes of healthy donors is very low, and the CKAP4 has remarkable specificity. Therefore, the detection means based on the urine exosome CKAP4 is a non-invasive liquid biopsy method which is low in cost, simple and convenient, can meet the requirement for multiple times of detection, and is particularly suitable for diagnosis and relapse monitoring of bladder cancer patients.

Despite the notion that human CD8⁺ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8⁺ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.

The present invention relates to a non-invasive, specific and rapid diagnostic method of Familial Mediterranean fever (FMF) in a subject said method comprising the step of measuring the level of cytokine (IL-18 or IL-1 beta) secreted by immune primary cells (or cell death level of these cells) obtained from said subject, which have been beforehand treated with a Protein Kinase C (PKC) inhibitor, and optionally beforehand treated with a NF-kB activator such as LPS. Inventors show based on the extensive study of the inflammasome process of the monocytes, that PKC superfamily inhibitors trigger inflammasome activation in monocytes from FMF patients while they are not sufficient to do so in monocytes from healthy donors (HD) or from patient having hyperimmunoglobulinemia D syndrome (HID S). Using cytokine release quantification or determination of real time cell death kinetics, inventors demonstrate that PKC superfamily inhibitors can discriminate FMF patients from HD or from patients with systemic inflammation from other aetiologies. These results thus set-up the basis for the development of a rapid functional specific diagnostic test for FMF. Methods of treatment are disclosed.